Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM)

• DOI: 10.1016/j.clml.2019.09.191
• Publication Date: 2019-10-18T07:29:08Z
• Authors: Robert Cornell; Hari Parameswaran; Shijie Tang; Alyssa Barnstead; Noa Biran; Natalie Callander; Ajai Chari; Saurabh Chhabra; Mark Fiala; Zhubin Gahvari; Ujjawal Gandhi; Kelly Godby; Ridhi Gupta; Sundar Jagannath; Megan Jagosky; Yubin Kang; Ankit Kansagra; Michael Kauffman; Saranya Kodali; Shaji Kumar; Arjun Lakshman; Michaela Liedtke; Sagar Lonial; Xiwen Ma; Ehsan Malek; Joshua Mansour; Elizabeth McGehee; Swapna Narayana; Amarendra Neppalli; Barry Paul; Paul G. Richardson; Emma Scott; Sharon Shacham; Jatin Shah; David S. Siegel; Elvira Umyarova; Saad Usmani; William Varnado; Ravi Vij; Luciano Costa
• Keywords: Daratumumab; Pomalidomide; Refractory (planetary science)